Ryan McDonald | Authors


Two Lenvatinib Combos Induce Survival Benefit Over Sunitinib in Advanced RCC

February 15, 2021

Findings from the phase 3 CLEAR trial showed that the addition of lenvatinib to either pembrolizumab or everolimus led to an improvement in survival and response rates in comparison with sunitinib monotherapy in the first-line setting for patients with advanced renal cell carcinoma.

BMS-986012 Combined With Nivolumab Demonstrates Preliminary Efficacy in Relapsed/Refractory SCLC

January 28, 2021

In patients with relapsed/refractory small cell lung cancer who did not receive previous checkpoint inhibitor therapy, the addition of the anti–fucosyl-GM1 monoclonal antibody, BMS-986012 to nivolumab demonstrated promising results in a phase 1/2 study.

Pembrolizumab/Trastuzumab Regimen Effective in Treating HER2-Positive Advanced Gastric, GEJ Cancer

January 15, 2021

The addition of pembrolizumab and trastuzumab to the combination cisplatin plus capecitabine was able to effectively treat HER2-positive advanced gastric and gastroesophageal junction cancer, regardless of PD-L1 expression in the phase 1b/2 PANTHERA trial.